Vivo Capital LLC cut its position in Soleno Therapeutics Inc (NASDAQ:SLNO) by 72.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,033,534 shares of the company’s stock after selling 10,661,730 shares during the quarter. Soleno Therapeutics comprises about 1.6% of Vivo Capital LLC’s portfolio, making the stock its 17th biggest holding. Vivo Capital LLC owned approximately 20.96% of Soleno Therapeutics worth $7,260,000 at the end of the most recent reporting period.
Separately, Birchview Capital LP acquired a new position in shares of Soleno Therapeutics during the 4th quarter worth $1,032,000. 46.56% of the stock is currently owned by institutional investors and hedge funds.
Soleno Therapeutics Inc (SLNO) opened at $1.89 on Tuesday. The stock has a market capitalization of $36.36, a P/E ratio of -1.18 and a beta of 5.27. Soleno Therapeutics Inc has a fifty-two week low of $1.32 and a fifty-two week high of $4.00.
SLNO has been the subject of a number of recent research reports. Maxim Group set a $8.00 target price on Soleno Therapeutics and gave the stock a “buy” rating in a report on Friday, December 8th. ValuEngine upgraded Soleno Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Finally, reduced their price target on Soleno Therapeutics from $25.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, November 15th.
In related news, Director Edgar Engleman acquired 1,085,480 shares of the stock in a transaction dated Friday, December 15th. The stock was purchased at an average cost of $1.84 per share, with a total value of $1,997,283.20. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 69.75% of the company’s stock.
WARNING: This piece of content was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/03/13/vivo-capital-llc-lowers-stake-in-soleno-therapeutics-inc-slno.html.
Soleno Therapeutics Company Profile
Soleno Therapeutics, Inc, formerly Capnia, Inc, is a healthcare company that develops and commercializes neonatology devices and diagnostics. The Company also has a therapeutics platform based on its proprietary technology for precision metering of gas flow. The Company offers products, such as CoSense end-tidal carbon monoxide (ETCO) Monitor, NeoPIP Infant Resuscitator and Accessories, and Serenz Nasal Relief.
Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.